References
- World Health Organization [Internet]. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012; 2014 [cited 2014 December 30]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
- BookmanMA. First-line chemotherapy in epithelial ovarian cancer. Clin. Obstet. Gynecol. 2012;55(1):96–113.
- JinY, LiY, PanL. The target therapy of ovarian clear cell carcinoma. Onco Targets Ther. 2014;7:1647–52.
- FracassoPM, BlessingJA, MorganMA, SoodAK, HoffmanJS. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J. Clin. Oncol. 2003;21(15):2856–9.
- RuggieroA, TrombatoreG, TriaricoS, ArenaR, FerraraP, ScalzoneM, et al.Platinum compounds in children with cancer: toxicity and clinical management. Anticancer Drugs. 2013;24(10):1007–19.
- StordalB, PavlakisN, DaveyR. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat. Rev. 2007;33(4):347–57.
- TaylorSE, BeckTL, KrivakTC, ZornKK, KelleyJL, EdwardsRP. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity. Gynecol. Oncol. 2014;134(1):68–72.
- PiccartMJ, GreenJA, LacaveAJ, ReedN, VergoteI, Benedetti-PaniciP, et al.Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J. Clin. Oncol. 2000;18(6):1193–202.
- KlintmalmGB, NashanB. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J. Transplant. 2014;2014:845438.
- LuX, WeiH, ZhangX, ZhengW, ChangC, GuJ. Rapamycin synergizes with low-dose oxaliplatin in the HCT116 colon cancer cell line by inducing enhanced apoptosis. Oncol. Lett. 2011;2(4):643–7.
- KawadaJI, ItoY, IwataS, SuzukiM, KawanoY, KanazawaT, et al.mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Clin. Cancer Res. 2014;20(21):5412–22.
- RajeN, KumarS, HideshimaT, IshitsukaK, ChauhanD, MitsiadesC, et al.Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004;104(13):4188–93.
- MatsuzakiT, YashiroM, KaizakiR, YasudaK, DoiY, SawadaT, et al.Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci. 2009;100(12):2402–10.
- PencreachE, GuerinE, NicoletC, Lelong-RebelI, VoegeliAC, OudetP, et al.Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin. Cancer Res. 2009;15(4):1297–307.
- GrothCG, BackmanL, MoralesJM, CalneR, KreisH, LangP, et al.Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67(7):1036–42.
- BrattstromC, TydenG, SaweJ, HerleniusG, ClaessonK, GrothCG. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant. Proc. 1996;28(2):985–6.
- Drug label of oxaliplatin for injection. Paris, France: Sanofi-Aventis. 2014.
- NoordhuisP, LaanAC, van de BornK, LosekootN, KathmannI, PetersGJ. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines. Biochem. Pharmacol. 2008;76(1):53–61.
- ZdraveskiZZ, MelloJA, FarinelliCK, EssigmannJM, MarinusMG. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J. Biol. Chem. 2002;277(2):1255–60.
- GourdierI, CrabbeL, AndreauK, PauB, KroemerG. Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene. 2004;23(45):7449–57.
- FujieY, YamamotoH, NganCY, TakagiA, HayashiT, SuzukiR, et al.Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn. J. Clin. Oncol. 2005;35(8):453–63.
- GaoR, TangW, GeX, JiangL, LuoJ. Effect of mTOR pathway on carboplatin resistance in ovarian cancer cells. Chin. Hosp. Pharm. J. 2012;32:1536–9.
- BeuvinkI, BoulayA, FumagalliS, ZilbermannF, RuetzS, O'ReillyT, et al.The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005;120(6):747–59.